ArticleBlood2016
KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.
Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- KIR3DL1 and HLA-Bw4 Interaction Showed a Favorable Role in Patients with Myelodysplastic Syndromes in Chinese Southern Han.BioMed research international · 2020Trial
- A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome.Clinical lymphoma, myeloma & leukemia · 2018Trial
- Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed/refractory neuroblastomas post autologous hematopoietic stem cell transplantation.Scientific reports · 2024Article
- Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.HemaSphere · 2024Article
- Polymorphisms of Killer Ig-like Receptors and the Risk of Glioblastoma.Journal of clinical medicine · 2023Article
- Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia.Blood advances · 2023Article
- Checkpoint Inhibitors in Acute Myeloid Leukemia.Biomedicines · 2023Review
- Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation.Nature communications · 2023Article
- Combined flow cytometry natural killer immunophenotyping and KIR/HLA-C genotyping reveal remarkable differences in acute myeloid leukemia patients, but suggest an overall impairment of the natural killer response.Frontiers in medicine · 2023Article
- Natural killer cells in liver transplantation: Can we harness the power of the immune checkpoint to promote tolerance?Clinical and translational science · 2022Review
- The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification.Frontiers in immunology · 2022Review
- From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review.Diagnostics (Basel, Switzerland) · 2021Review
- Natural Killer Cells: Friend or Foe in Metabolic Diseases?Frontiers in immunology · 2021Review
- Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-α and IL-32 Levels in Myelodysplastic Syndrome Patients.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.Frontiers in immunology · 2020Article
- Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions.Frontiers in immunology · 2020Article
- Natural Killer Cells Offer Differential Protection From Leukemia in Chinese Southern Han.Frontiers in immunology · 2019Article
- Cancer treatment and the KIR-HLA system: an overview.Clinical and experimental medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 2 countries.
Funding
Abstract
Myelodysplastic syndromes (MDSs) are a group of hematopoietic disorders affecting the myeloid lineage, characterized by cytopenias and clonal evolution to acute myeloid leukemia (AML). We hypothesized that natural killer (NK) cells and their activating killer immunoglobulin-like receptors (aKIRs) influence the immune surveillance and clinical outcome of patients with MDSs. Here, we first examined the distribution of aKIR genes and haplotype in 2 independent cohorts of MDS and AML patients. The median number of aKIR genes was lower in MDS patients than healthy controls (2 vs 3 genes; P = .001), and lower in patients with secondary AML (progressed from MDSs) compared with de novo AML patients (2 vs 3; P = .008) and healthy controls (2 vs 3; P = .006). In a multivariate analysis, the presence of KIR haplotype A (characterized by low aKIR content 0-1) independently predicted a higher risk of conversion to AML (relative risk [RR] with 95% confidence interval [CI], 2.67 [1.13-6.71]; P = .02) and worse adjusted progression-free survival (RR with 95% CI, 2.96 [1.59-5.52]; P = .001) and overall survival (2.25 [1.17-4.31]; P = .02), compared with KIR haplotype B (multiple aKIR genes). These novel findings may help to identify MDS patients with a high risk of disease progression who would likely benefit from adoptive NK-cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.